Nuclear medicine is an essential tool in the delivery of high-quality medical care, going
beyond simple anatomic imaging to the use of physiologic processes for both imaging and …

Thyroid disease management has changed little over the last 60 years and recent work
suggests that the older approach remains the most effective. Treatment of benign …

The term theranostics is the combination of a diagnostic tool that helps to define the right
therapeutic tool for specific disease. It signifies the “we know which sites require treatment …

Nuclear medicine has been used in the evaluation and treatment of benign and malignant
thyroid disease since the discovery of iodine 131 ((131) I) in the 1930s. Although traditional …

Thefirst reports of radionuclide therapy for thyroid disease used 130I, but 131I rapidly
became the favoured radionuclide with beta-and gamma-ray emissions and a half-life …

Radioiodine is important in the diagnostic and therapeutic armamentarium of differentiated
thyroid cancer (DTC); however, many controversies persist. This article addresses some of …

Radioiodine therapy is a matter of controversy because different opinions exist about its use
for differentiated thyroid carcinoma. The following article sheds light on the different opinions …

The purpose of this guideline is to assist nuclear medicine practitioners in evaluating
patients for therapy with 131I (sodium iodide) for benign or malignant conditions of the …

This article discusses several aspects of the evaluation and management of differentiated
thyroid carcinoma that are changing or may change in the near future. Although …

Radioiodine has served an important role in the diagnostic workup and treatment of patients
with differentiated thyroid cancer for more than 6 decades. The interpretation of radioiodine …